Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer
1. Median overall survival was 3.1 months greater in the nivolumab plus ipilimumab group. 2. Grade 3-4 treatment-related adverse events ...
Tag: hepatic failure
#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma
Click to read this study in The Lancet Oncology.
Study reports improvement in pediatric liver transplant outcomes over past decades
1. In approximately 14,000 pediatric patients across Europe who received a liver transplant between 1968-2017, the overall survival rate improved ...
